))
Part One: Why Do We Need to Continue Innovating in the CGT Industry?
Manage episode 440149608 series 2994360
Indhold leveret af Adam.Roberts@ttp.com and TTP plc. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Adam.Roberts@ttp.com and TTP plc eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?
Guests:
- Tay Salimullah, Chief Access Commercial Officer at Novartis
- Jason Jones, Global Business Development Lead at Cellular Origins
23 episoder
Del
